PL2961426T3 - Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny g - Google Patents
Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny gInfo
- Publication number
- PL2961426T3 PL2961426T3 PL14714815T PL14714815T PL2961426T3 PL 2961426 T3 PL2961426 T3 PL 2961426T3 PL 14714815 T PL14714815 T PL 14714815T PL 14714815 T PL14714815 T PL 14714815T PL 2961426 T3 PL2961426 T3 PL 2961426T3
- Authority
- PL
- Poland
- Prior art keywords
- oxygening
- immunoglobulin
- disorders
- treatment
- nervous system
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361769673P | 2013-02-26 | 2013-02-26 | |
| US201361862814P | 2013-08-06 | 2013-08-06 | |
| PCT/US2014/018426 WO2014134070A1 (en) | 2013-02-26 | 2014-02-25 | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g |
| EP14714815.9A EP2961426B1 (en) | 2013-02-26 | 2014-02-25 | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2961426T3 true PL2961426T3 (pl) | 2020-02-28 |
Family
ID=50424697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14714815T PL2961426T3 (pl) | 2013-02-26 | 2014-02-25 | Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny g |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9556260B2 (pl) |
| EP (2) | EP2961426B1 (pl) |
| JP (1) | JP6379113B2 (pl) |
| AU (2) | AU2014223679B2 (pl) |
| DK (1) | DK2961426T3 (pl) |
| ES (1) | ES2759226T3 (pl) |
| HR (1) | HRP20192111T1 (pl) |
| HU (1) | HUE046752T2 (pl) |
| LT (1) | LT2961426T (pl) |
| PL (1) | PL2961426T3 (pl) |
| PT (1) | PT2961426T (pl) |
| SI (1) | SI2961426T1 (pl) |
| WO (1) | WO2014134070A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150100042A1 (en) * | 2013-10-07 | 2015-04-09 | Impel Neuropharma Inc. | Muroid Family Nasal Device |
| EP3129013A1 (en) * | 2014-04-10 | 2017-02-15 | Crowley, Patrick | Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング,インコーポレイテッド | Tim-3とそのリガンドとの相互作用の遮断によるがん治療 |
| US11331270B2 (en) | 2017-08-20 | 2022-05-17 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| WO2020163815A1 (en) * | 2019-02-07 | 2020-08-13 | Innomed Technologies, Inc. | Ivig treatments for bell's palsy |
| EP3990440A4 (en) * | 2019-06-28 | 2022-09-07 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF DISEASES OF THE NEUROMYELITIS OPTICA SPECTRUM |
| CA3148026A1 (en) * | 2019-08-13 | 2021-02-18 | Vyjayanthi Krishnan | Therapeutic agent effectiveness and its route of administration |
| CA3185040A1 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| EP3991573A1 (de) * | 2020-11-03 | 2022-05-04 | Patrick Faber | Zusammensetzungen zur nasalen applikation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (pl) | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| WO1996022802A1 (en) | 1995-01-23 | 1996-08-01 | Direct-Haler A/S | An inhaler |
| MXPA01008849A (es) | 1999-03-03 | 2003-07-21 | Optinose As | Dispositivo de administracion nasal. |
| US6585957B1 (en) | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| US20070254889A1 (en) * | 2001-04-23 | 2007-11-01 | Lee-Way Jin | Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease |
| WO2003028668A2 (en) | 2001-10-04 | 2003-04-10 | Protein Therapeutics, Inc. | Gammaglobulin treatment of immune disorders |
| US20040101909A1 (en) | 2002-08-20 | 2004-05-27 | Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 | Purification of polyreactive autoantibodies and uses thereof |
| US20090136505A1 (en) | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
| CA2598666A1 (en) | 2005-02-23 | 2006-08-31 | Alza Corporation | Intranasal administration of active agents to the central nervous system |
| US9084777B2 (en) * | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
| JP5697847B2 (ja) * | 2006-01-30 | 2015-04-08 | グリフオルス・セラピユーテイクス・インコーポレーテツドGrifols Therapeutics,Inc. | IgMを使用する治療方法および予防方法 |
| US20090317324A1 (en) * | 2006-02-15 | 2009-12-24 | Ramot At Tel Aviv University | Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain |
| WO2008154337A1 (en) | 2007-06-08 | 2008-12-18 | Healthpartners Research Foundation | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
| EP2257804B1 (en) * | 2008-02-29 | 2013-12-11 | Baxter International Inc. | Anti-amyloid activity of intravenous immunoglobulin (ivig) in vitro |
| US8622993B2 (en) | 2009-12-18 | 2014-01-07 | Healthpartners Research Foundation | Device and method for delivering therapeutic substances to the maxillary sinus of a patient |
| EP2531218B1 (en) | 2010-02-04 | 2018-12-12 | CSL Behring AG | Immunoglobulin preparation |
| US8772462B2 (en) * | 2010-05-26 | 2014-07-08 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
-
2014
- 2014-02-25 ES ES14714815T patent/ES2759226T3/es active Active
- 2014-02-25 PT PT147148159T patent/PT2961426T/pt unknown
- 2014-02-25 PL PL14714815T patent/PL2961426T3/pl unknown
- 2014-02-25 JP JP2015559285A patent/JP6379113B2/ja active Active
- 2014-02-25 WO PCT/US2014/018426 patent/WO2014134070A1/en not_active Ceased
- 2014-02-25 SI SI201431417T patent/SI2961426T1/sl unknown
- 2014-02-25 EP EP14714815.9A patent/EP2961426B1/en active Active
- 2014-02-25 EP EP19197257.9A patent/EP3597220A1/en not_active Withdrawn
- 2014-02-25 DK DK14714815T patent/DK2961426T3/da active
- 2014-02-25 LT LTEP14714815.9T patent/LT2961426T/lt unknown
- 2014-02-25 HU HUE14714815A patent/HUE046752T2/hu unknown
- 2014-02-25 US US14/189,981 patent/US9556260B2/en active Active
- 2014-02-25 AU AU2014223679A patent/AU2014223679B2/en active Active
- 2014-02-25 HR HRP20192111TT patent/HRP20192111T1/hr unknown
-
2016
- 2016-10-26 US US15/335,027 patent/US10144776B2/en active Active
-
2018
- 2018-10-19 US US16/165,993 patent/US20190055307A1/en not_active Abandoned
- 2018-11-08 AU AU2018260883A patent/AU2018260883B2/en not_active Expired - Fee Related
-
2020
- 2020-12-14 US US17/121,553 patent/US11851481B2/en active Active
-
2023
- 2023-11-13 US US18/507,265 patent/US12503501B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10144776B2 (en) | 2018-12-04 |
| EP2961426B1 (en) | 2019-10-30 |
| DK2961426T3 (da) | 2019-12-02 |
| US20240117025A1 (en) | 2024-04-11 |
| US20190055307A1 (en) | 2019-02-21 |
| US20210101967A1 (en) | 2021-04-08 |
| PT2961426T (pt) | 2019-12-09 |
| WO2014134070A1 (en) | 2014-09-04 |
| AU2014223679A1 (en) | 2015-09-24 |
| EP3597220A1 (en) | 2020-01-22 |
| LT2961426T (lt) | 2019-12-27 |
| ES2759226T3 (es) | 2020-05-08 |
| US20140242067A1 (en) | 2014-08-28 |
| EP2961426A1 (en) | 2016-01-06 |
| HUE046752T2 (hu) | 2020-03-30 |
| JP6379113B2 (ja) | 2018-08-22 |
| US9556260B2 (en) | 2017-01-31 |
| JP2016512490A (ja) | 2016-04-28 |
| US20170044244A1 (en) | 2017-02-16 |
| SI2961426T1 (sl) | 2020-01-31 |
| US12503501B2 (en) | 2025-12-23 |
| AU2014223679B2 (en) | 2018-11-29 |
| AU2018260883B2 (en) | 2020-08-06 |
| US11851481B2 (en) | 2023-12-26 |
| HRP20192111T1 (hr) | 2020-03-20 |
| AU2018260883A1 (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268987B (en) | System for glaucoma treatment | |
| IL271085A (en) | Bacteria for the treatment of disorders | |
| HUE061618T2 (hu) | Vegyület szemrendellenességek kezelésére | |
| PL2961426T3 (pl) | Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny g | |
| IL247452A0 (en) | Compounds for treatment of complement mediated disorders | |
| IL257252A (en) | Methods of treating fgf21-associated disorders | |
| PL3060252T3 (pl) | Zastosowanie cząsteczek wiążących semaforynę-4D do leczenia zaburzeń neurodegeneracyjnych | |
| HUE059041T2 (hu) | Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására | |
| DK2983787T3 (da) | Fremgangsmåde til behandling af posttraumatisk stresssygdom | |
| HUE047719T2 (hu) | Pirazolopirimidin-származékok alkalmazása PI3K-hoz kapcsolódó rendellenességek kezelésére | |
| EP3761223C0 (en) | AUTONOMOUS LANE OFFSET ADJUSTMENT | |
| HRP20181679T1 (hr) | Amidni spojevi za liječenje hiv | |
| DK3110843T3 (da) | Kombinationsterapier med anti-cd38-antistoffer | |
| DK3065818T3 (da) | Anordning til behandling af sygdomme i centralnervesystemet ved hjælp af sansestimulering | |
| HUE043206T2 (hu) | Kortisztatin-analógok gyulladásos és/vagy immunbetegségek kezelésére | |
| DK3062811T3 (da) | Angiopoietin-baserede interventioner til behandling af cerebral malaria | |
| HUE037179T2 (hu) | Gyógyászati kompozíciók izom-rendellenességek kezelésére | |
| DK3192524T3 (da) | Hgf præparat egnet til behandling af neurologiske lidelser | |
| HUS2000037I1 (hu) | Triazinok Protozoa okozta betegségek kezelésére | |
| LT3250600T (lt) | Autoimuninių sutrikimų gydymas cd154 antikūnais | |
| IL263080B (en) | Treatment of neurological disorders | |
| ZA201507724B (en) | The treatment of inflammatory disorders | |
| DK2964185T3 (da) | Præparater til behandlingen af søvnrelaterede luftvejslidelser | |
| HUE042199T2 (hu) | Pantotenát-származékok neurológiai rendellenességek kezelésére | |
| SI2986325T1 (sl) | Postopki zdravljenja motenj ciklusa sečnine |